{"DataElement":{"publicId":"2738883","version":"2","preferredName":"Susceptibility Disease or Disorder Occurrence Name","preferredDefinition":"A description of the predisposing condition.","longName":"SUSC_DISE_OCC_NAME","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2738874","version":"1","preferredName":"Susceptibility Disease or Disorder Occurrence","preferredDefinition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Occurrence; an instance of something happening.","longName":"SU_DIS_OC","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2738871","version":"1","preferredName":"Susceptibility Disease or Disorder","preferredDefinition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C16505:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Susceptibility","conceptCode":"C16505","definition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49F9F5A0-E964-2841-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-04-03","modifiedBy":"ONEDATA","dateModified":"2008-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49F9F5A0-E988-2841-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-04-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2738881","version":"1.1","preferredName":"Susceptibility Disease or Disorder Name","preferredDefinition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The words or language units by which a thing is known.","longName":"SUSC_DIS_NAME","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aplastic anemia","valueDescription":"Aplastic Anemia","ValueMeaning":{"publicId":"2593270","version":"1","preferredName":"Aplastic Anemia","longName":"2593270","preferredDefinition":"A condition in which the bone marrow is unable to produce blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia","conceptCode":"C2870","definition":"Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880D74E-659D-0A0D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E7308B1-45F0-77DB-E063-731AD00AE263","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2024-01-08","modifiedBy":"STURGILLJ","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Bloom syndrome","valueDescription":"Bloom Syndrome","ValueMeaning":{"publicId":"2730287","version":"1","preferredName":"Bloom Syndrome","longName":"2730287","preferredDefinition":"Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. (Oncogene 2001 Dec 13;20(57):8276-80)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bloom Syndrome","conceptCode":"C2903","definition":"Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. (Oncogene 2001 Dec 13;20(57):8276-80)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468669DD-2FE6-4A98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E7308B1-45F1-77DB-E063-731AD00AE263","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2024-01-08","modifiedBy":"STURGILLJ","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Fanconi anemia","valueDescription":"Fanconi anemia","ValueMeaning":{"publicId":"2579909","version":"1","preferredName":"Fanconi anemia","longName":"2579909","preferredDefinition":"A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0532-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E7308B1-45F2-77DB-E063-731AD00AE263","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2024-01-08","modifiedBy":"STURGILLJ","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Down Syndrome","valueDescription":"Down Syndrome","ValueMeaning":{"publicId":"2730288","version":"1","preferredName":"Down Syndrome","longName":"2730288","preferredDefinition":"A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Down Syndrome","conceptCode":"C2993","definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468669DD-300B-4A98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E7308B1-45F3-77DB-E063-731AD00AE263","beginDate":"2008-04-03","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2024-01-08","modifiedBy":"STURGILLJ","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Other condition","valueDescription":"Other Condition","ValueMeaning":{"publicId":"3031159","version":"1","preferredName":"Other Condition","longName":"3031159","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A state of being, such as a state of health.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Condition","conceptCode":"C25457","definition":"A state of being, such as a state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F0310E-A80A-A1C1-E040-BB89AD430D90","latestVersionIndicator":"Yes","beginDate":"2010-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-03-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E7308B1-45F4-77DB-E063-731AD00AE263","beginDate":"2008-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"ONEDATA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Germline DDX41 variant","valueDescription":null,"ValueMeaning":{"publicId":"7161778","version":"1","preferredName":"Myeloid Neoplasms with Germline DDX41 Mutation","longName":"7161778","preferredDefinition":"An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Neoplasm with Germline DDX41 Mutation","conceptCode":"C151901","definition":"An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DDAE0B5-A770-3664-E053-F662850A71C9","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CC7-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Li-Fraumeni Syndrome","valueDescription":null,"ValueMeaning":{"publicId":"3211225","version":"1","preferredName":"Li-Fraumeni Syndrome","longName":"3211225","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Li-Fraumeni Syndrome","conceptCode":"C3476","definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF6B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CC8-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Germline RUNX1 variant","valueDescription":null,"ValueMeaning":{"publicId":"14673091","version":"1","preferredName":"Hematologic Neoplasm with Germline RUNX1 Mutation","longName":"14673091v1.00","preferredDefinition":"An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Neoplasm with Germline RUNX1 Mutation","conceptCode":"C151903","definition":"An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC1-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CC9-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Germline ANKRD26 variant","valueDescription":null,"ValueMeaning":{"publicId":"14673092","version":"1","preferredName":"Hematologic Neoplasm with Germline ANKRD26 Mutation","longName":"14673092v1.00","preferredDefinition":"An autosomal dominant disorder characterized by moderate thrombocytopenia and increased risk of developing myelodysplastic syndrome/acute myeloid leukemia. This disorder is characterized by germline mutations in ANKRD26, located on chromosome band 10p12.1. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Neoplasm with Germline ANKRD26 Mutation","conceptCode":"C151908","definition":"An autosomal dominant disorder characterized by moderate thrombocytopenia and increased risk of developing myelodysplastic syndrome/acute myeloid leukemia. This disorder is characterized by germline mutations in ANKRD26, located on chromosome band 10p12.1. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC2-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CCA-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Germline ETV6 variant","valueDescription":null,"ValueMeaning":{"publicId":"14673093","version":"1","preferredName":"Thrombocytopenia 5","longName":"14673093v1.00","preferredDefinition":"An autosomal dominant disorder characterized by decreased platelets, bleeding tendency, and mutation in the ETV6 gene. It is associated with an increased risk of developing hematologic malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombocytopenia 5","conceptCode":"C203436","definition":"An autosomal dominant disorder characterized by decreased platelets, bleeding tendency, and mutation in the ETV6 gene. It is associated with an increased risk of developing hematologic malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC3-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CCB-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Germline PAX5 mutation","valueDescription":null,"ValueMeaning":{"publicId":"14673094","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with Germline PAX5 Mutation","longName":"14673094v1.00","preferredDefinition":"B-acute lymphoblastic leukemia that results from germline mutation of the PAX5 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with Germline PAX5 Mutation","conceptCode":"C198684","definition":"B-acute lymphoblastic leukemia that results from germline mutation of the PAX5 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC4-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CCC-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"Germline IKZF1 mutation","valueDescription":null,"ValueMeaning":{"publicId":"14673095","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with Germline IKZF1 Mutation","longName":"14673095v1.00","preferredDefinition":"B-acute lymphoblastic leukemia that results from germline mutation of the IKZF1 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with Germline IKZF1 Mutation","conceptCode":"C198685","definition":"B-acute lymphoblastic leukemia that results from germline mutation of the IKZF1 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC5-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E731DB4-4CCD-7E61-E063-731AD00AF6BF","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","deletedIndicator":"No"},{"value":"DDX41-associated familial MDS","valueDescription":null,"ValueMeaning":{"publicId":"7161778","version":"1","preferredName":"Myeloid Neoplasms with Germline DDX41 Mutation","longName":"7161778","preferredDefinition":"An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Neoplasm with Germline DDX41 Mutation","conceptCode":"C151901","definition":"An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DDAE0B5-A770-3664-E053-F662850A71C9","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8694-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Diamond-Blackfan Anemia","valueDescription":null,"ValueMeaning":{"publicId":"3322760","version":"1","preferredName":"Diamond-Blackfan Anemia PT: Congenital Pure Red Cell Aplasia","longName":"3322760","preferredDefinition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Pure Red Cell Aplasia","conceptCode":"C61236","definition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A77C-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8695-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"GATA2 deficiency","valueDescription":null,"ValueMeaning":{"publicId":"5207249","version":"1","preferredName":"GATA2 Deficiency","longName":"5207249","preferredDefinition":"A condition of decreased or absent presence or activity of endothelial transcription factor GATA-2 protein. Deficiency of this protein is associated with immunodeficiency 21 and autosomal dominant and sporadic monocytopenia and mycobacterial infection syndrome (MonoMAC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GATA2 Deficiency","conceptCode":"C126349","definition":"A condition of decreased or absent presence or activity of endothelial transcription factor GATA-2 protein. Deficiency of this protein is associated with immunodeficiency 21 and autosomal dominant and sporadic monocytopenia and mycobacterial infection syndrome (MonoMAC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F499E09-4512-CF28-E050-BB89AD4321FA","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-03-30","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8696-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Paroxysmal nocturnal hemoglobinuria","valueDescription":null,"ValueMeaning":{"publicId":"2593267","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria","longName":"2593267","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880CCB0-13F1-07E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8697-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"RUNX1 deficiency","valueDescription":null,"ValueMeaning":{"publicId":"14673091","version":"1","preferredName":"Hematologic Neoplasm with Germline RUNX1 Mutation","longName":"14673091v1.00","preferredDefinition":"An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Neoplasm with Germline RUNX1 Mutation","conceptCode":"C151903","definition":"An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E731DB4-4CC1-7E61-E063-731AD00AF6BF","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8698-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"SAMD9- or SAMD9L-associated familial MDS","valueDescription":null,"ValueMeaning":{"publicId":"7161774","version":"1","preferredName":"SAMD9-Associated Familial Myelodysplastic Syndrome Or SAMD9L-Associated Familial Myelodysplastic Syndrome","longName":"7161774","preferredDefinition":"A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9 gene.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9L gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SAMD9-Associated Hereditary Myelodysplastic Syndrome","conceptCode":"C168746","definition":"A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"SAMD9L-Associated Hereditary Myelodysplastic Syndrome","conceptCode":"C168747","definition":"A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9L gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DDAE0B5-A6DE-3664-E053-F662850A71C9","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-8699-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Shwachman-Diamond Syndrome","valueDescription":null,"ValueMeaning":{"publicId":"5651021","version":"1","preferredName":"Shwachman-Diamond Syndrome","longName":"5651021","preferredDefinition":"A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Shwachman-Diamond Syndrome","conceptCode":"C61235","definition":"A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"479020AD-0C96-3909-E053-F662850A62CA","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-869A-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Telomere biology disorder","valueDescription":null,"ValueMeaning":{"publicId":"7161773","version":"1","preferredName":"Telomere Syndrome","longName":"7161773","preferredDefinition":"A group of disorders caused by mutation(s) that disrupt the maintenance of telomeres, resulting in the short telomere defect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Telomere Syndrome","conceptCode":"C152065","definition":"A group of disorders caused by mutation(s) that disrupt the maintenance of telomeres, resulting in the short telomere defect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DDAE0B5-A6A3-3664-E053-F662850A71C9","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EAE8DF2-869B-2BED-E063-731AD00A8A0A","beginDate":"2024-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3031134","version":"1","preferredName":"Susceptibility Disease or Disorder Name","preferredDefinition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:The words or language units by which a thing is known.","longName":"C16505:C2991:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Susceptibility","conceptCode":"C16505","definition":"The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F0310E-A676-A1C1-E040-BB89AD430D90","latestVersionIndicator":"Yes","beginDate":"2010-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-03-29","modifiedBy":"ONEDATA","dateModified":"2010-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0E7308B5-0795-77D3-E063-731AD00AAF57","latestVersionIndicator":"Yes","beginDate":"2008-04-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-11","changeDescription":".Added PV \"Neurofibromatosis type 1\" AK 1010/13 Added PV for 2402r2. AK 4/20/17. Added PVs for F2402r5 02/05/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964927","version":"1","longName":"2010r1: Acute Myelogenous Leukemia Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964928","version":"1","longName":"2011r1: ALL Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964931","version":"1","longName":"2014r1: MDS Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279257","version":"1","longName":"2127r1: Renal Carcinoma Post-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"mds_base_predisp_cond_spc","type":"NMDP_FN","context":"NHLBI"},{"name":"all_base_predisp_cond_spc","type":"NMDP_FN","context":"NHLBI"},{"name":"aml_base_predisp_cond_spc","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_predispose_cond_aml_name","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_predispose_cond_mds_name","type":"NMDP_FN","context":"NHLBI"},{"name":"ALLpre_assess_diag_predispose_cond_all_name","type":"NMDP_FN","context":"NHLBI"},{"name":"AMLpre_assess_diag_predispose_cond_name","type":"NMDP_FN","context":"NHLBI"},{"name":"MDSpre_assess_diag_predispose_cond_mds_name","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_AML_predis_cond_aml_name","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_MDS_predis_cond_mds_name","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_ALL_predis_cond_all_name","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Specify predisposing condition:","url":null,"context":"NHLBI"},{"name":"Specify condition:","type":"Alternate Question Text","description":"Specify condition:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2738883","type":"BRIDG Mapping Path","description":"\"PerformedDiagnosis [primary] > AssessedResultRelationship > PerformedObservation [assessment] > AssessedResultRelationship > PerformedDiagnosis.value [secondary] WHERE PerformedDiagnosis.value [primary] = \"\"Acute Myelogenous Leukemia(AML)\"\" OR \"\"Myelodysplasia Syndrome(MDS)\"\" AND PerformedObservation [assessment] > PerformedClinicalInterpretation.value = \"\"Susceptability\"\"\"","url":null,"context":"NHLBI"},{"name":"Specify condition","type":"Application Standard Question Text","description":"Specify condition","url":null,"context":"NHLBI"},{"name":"Specify condition","type":"Alternate Question Text","description":"Specify condition","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0E735BC1-C184-149C-E063-731AD00A8765","latestVersionIndicator":"Yes","beginDate":"2008-04-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-08","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":". Added alt name/ASQT for 2400. AK 10/10/13. 6/11/14mn-added aqt for 2010 (w/out colon). Added human readable def. System generated def displayed as alt def. No version needed. AK 11/17/14. 11/19/14mn-added alt name for 2010r3.. 12/19/14mn-added alt name for 2011r4.","administrativeNotes":"2024.1.8 Newer version created to reflect VD update. ak","unresolvedIssues":null,"deletedIndicator":"No"}}